{"prompt": "['Appendix IV) at 4 time points: prior to initiating treatment, cycle 4 prior to', 'chemotherapy, completion of treatment and final study visit. Results recorded on', 'the CRFs. Trained site personnel are defined as site pharmacist, nursing staff,', 'clinician, or other trained clinical personnel (e.g., adherence counselors, social', 'workers). It is estimated that this assessment will take 10-15 minutes to complete.', '8.3', 'Treatment Discontinuation Evaluations', '8.3.1', 'All participants will have the following evaluations and laboratory tests within three', 'weeks of the last dose of protocol treatment, regardless of the reason for', 'discontinuation:', 'Physical examination including vitals, weight, and performance status', 'Toxicity evaluation', 'Tumor response evaluation, including radiologic evaluation for participants that', 'had visceral KS at baseline or those who have symptoms suggestive of visceral', 'KS at treatment discontinuation', 'CBC with differentials and platelets', 'Liver and renal function labs as defined in Section 8.1.5', 'Oxygen saturation level', 'FACT-G questionnaire', '8.4', 'Final Evaluations, Off Study', 'In addition to the evaluations listed below, the Off-Study Summary Form should be', 'completed in Advantage eClinical.', '8.4.1', 'All participants will have the following evaluations and laboratory tests within three', 'months of the last dose of protocol treatment, regardless of the reason for', 'discontinuation:', 'Physical examination including vitals, weight, and performance status', 'Toxicity evaluation', 'Tumor response evaluation, including radiologic evaluation for participants that', 'had visceral KS at baseline or those who have symptoms suggestive of visceral', 'KS at treatment discontinuation', 'CBC with differentials and platelets', 'Liver and renal function labs as defined in Section 8.1.5', 'Oxygen saturation level', 'FACT-G questionnaire', 'AMC-S007 (Version 2.0) 20MAR2018', '35', 'NCI Version Date 20MAR2018']['9.0', 'MEASUREMENT OF EFFECT', 'All participants will be evaluated for KS response by physical examination as described in', 'the AMC KS Tumor Assessment Manual of Procedures (MOP) within 3 days prior to the', 'first day of every cycle. See Appendix I for the KS Tumor Assessment schedule.', '9.1', 'Definition of Response', 'Response and progression will be evaluated in this study as follows:', '9.1.1 Complete response (CR): CR is defined as the absence of any detectable residual', 'disease, including tumor-associated edema, persisting for at least 4 weeks. In some', 'individuals, residual skin color changes may remain visible at one or more site(s)', 'of lesions that were previously raised and/or red or violaceous. Suspected CR in', 'those lesions refers only to residual macules (flat, non-palpable lesions) that are', 'slightly darker than the surrounding normal skin. If such lesions are present in a', 'participant otherwise believed to have a CR, biopsy of at least one such lesion is', 'required in order to document the absence of malignant cells and to confirm CR. In', 'the event that such a confirmatory biopsy is not performed and residual pigment', 'persists, the response will be considered partial (PR). In participants in whom all', 'detectable cutaneous disease has resolved and in whom there are no visible', 'pigmented macules as described above, a confirmatory skin biopsy is not required.', 'In participants known to have had visceral disease, an attempt at restaging with', 'appropriate endoscopic or radiographic procedures should be made.', 'NOTE: To classify a response as a CR, the participant must have a CR in both the', 'cutaneous and noncutaneous (if applicable) sites of disease and no evidence of', 'progression as defined by the above criteria.', '9.1.2 Partial response (PR): PR is defined as no new oral lesions or new or progressive', 'visceral sites of involvement, or the appearance or worsening of tumor-associated', 'edema (as defined in the MOP) or effusions or the development of five or more', 'new cutaneous lesions in anatomic sites which were previously documented as', 'having no evidence of cutaneous disease; AND', 'A 50% or greater decrease in the number of all lesions present at entry (either', 'total body or in the representative areas) lasting for at least 4 weeks; OR', 'Complete flattening of at least 50% of all previously raised lesions (i.e., 50% of', 'all nodular or plaque-like lesions become macules, either total body or in the', 'representative areas) present at entry lasting for at least 4 weeks; OR', 'A 50% or greater decrease in the area of the cutaneous marker lesions compared', 'with entry lasting for at least 4 weeks; OR', 'A 50% or greater decrease in the number or size of all measurable oral or', 'visceral lesions lasting for at least 4 weeks, without evidence for progression of', 'cutaneous lesions; OR', 'Complete disappearance of non-measurable oral or visceral lesions lasting for', 'at least 4 weeks, without evidence for progression of cutaneous lesions.', 'AMC-S007 (Version 2.0) 20MAR2018', '36', 'NCI Version Date 20MAR2018']\n\n###\n\n", "completion": "END"}